Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Apr 6;36(2):413–423. doi: 10.3803/EnM.2020.906

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Korean Endocrine Society

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Fig. 2 — Thyroid ultrasonographic findings in a 68-year-old male patient treated with programmed cell death 1 (PD-1) inhibitor pembrolizumab for renal cell carcinoma. He initiated to receive 125 μg/day of levothyroxine at 3 months after pembrolizumab. Thyroid ultrasonographic images (A) before therapy, (B) at 1 month after therapy, (C) at 15 months after therapy, and (D) at 40 months after therapy. TSH, thyroid stimulating hormone; T4, thyroxine; TPO, thyroid peroxidase; Tg, thyroglobulin. ^aOn levothyroxine replacement.